Paper41377006
Prediction of EGFR mutation status and mutation sites in lung cancer based on radiomics and deep learning.
Zeng Z and 7 others. J Thorac Dis, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Prediction of EGFR mutation status and mutation sites in lung cancer based on radiomics and deep learning. Papers, record 41377006. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41377006
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prediction of EGFR mutation status and mutation sites in lung cancer based on radiomics and deep learning.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38880172 | Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study. | J Thorac Oncol | 2024 | https://conductscience.org/library/papers/38880172 | PubMed |
| 2 | 29864379 | Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29864379 | PubMed |
| 3 | 28367239 | Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations. | J Cancer | 2017 | https://conductscience.org/library/papers/28367239 | PubMed |
| 4 | 14570950 | Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. | JAMA | 2003 | https://conductscience.org/library/papers/14570950 | PubMed |
| 5 | 35669165 | EGFR Mutation Status and Subtypes Predicted by CT-Based 3D Radiomic Features in Lung Adenocarcinoma. | Onco Targets Ther | 2022 | https://conductscience.org/library/papers/35669165 | PubMed |
| 6 | 32853681 | Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. | Ann Oncol | 2020 | https://conductscience.org/library/papers/32853681 | PubMed |
| 7 | 23780873 | EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. | Cancer Cytopathol | 2013 | https://conductscience.org/library/papers/23780873 | PubMed |
| 8 | 31278276 | Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. | Nat Commun | 2019 | https://conductscience.org/library/papers/31278276 | PubMed |
| 9 | 40328536 | Prediction of EGFR Mutations in Lung Adenocarcinoma via CT Images: A Comparative Study of Intratumoral and Peritumoral Radiomics, Deep Learning, and Fusion Models. | Acad Radiol | 2025 | https://conductscience.org/library/papers/40328536 | PubMed |
| 10 | 23749122 | Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes. | Lung | 2013 | https://conductscience.org/library/papers/23749122 | PubMed |
| 11 | 33067442 | Non-invasive decision support for NSCLC treatment using PET/CT radiomics. | Nat Commun | 2020 | https://conductscience.org/library/papers/33067442 | PubMed |
| 12 | 26490356 | Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis. | Eur J Clin Pharmacol | 2016 | https://conductscience.org/library/papers/26490356 | PubMed |
| 13 | 32953499 | 3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma. | Transl Lung Cancer Res | 2020 | https://conductscience.org/library/papers/32953499 | PubMed |
| 14 | 26937803 | CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma. | Radiology | 2016 | https://conductscience.org/library/papers/26937803 | PubMed |
| 15 | 24419411 | A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). | J Thorac Oncol | 2014 | https://conductscience.org/library/papers/24419411 | PubMed |
| 16 | 28958502 | Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28958502 | PubMed |
| 17 | 21725039 | Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. | J Clin Pathol | 2011 | https://conductscience.org/library/papers/21725039 | PubMed |
| 18 | 29151359 | Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29151359 | PubMed |
| 19 | 35341713 | Mining whole-lung information by artificial intelligence for predicting EGFR genotype and targeted therapy response in lung cancer: a multicohort study. | Lancet Digit Health | 2022 | https://conductscience.org/library/papers/35341713 | PubMed |
| 20 | 34502160 | Machine Learning-Based Radiomics Signatures for EGFR and KRAS Mutations Prediction in Non-Small-Cell Lung Cancer. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34502160 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41377006
GET https://conductscience.org/api/papers/v1/41377006/references?page=2